侵袭性淋巴瘤免疫化疗后国际预后指数意义的变化  

The impact of rituximab on the international prognostic index in aggressive B cell lymphoma

作　　者：刘海生[1] 史健[2] 杨淑琴[3] 黄晨[1] 高玉环[1] 

机构地区：[1]河北医科大学第四医院血液内科,石家庄市050011 [2]河北医科大学第四医院肿瘤内科,石家庄市050011 [3]河北省南皮县人民医院内三科

出　　处：《河北医药》2010年第10期1210-1212,共3页Hebei Medical Journal

基　　金：河北省普通高校强势特色学科项目[编号:冀教高(2005)52号];河北省医学科学研究重点课题计划(编号:20090154)

摘　　要：目的探讨侵袭性B细胞淋巴瘤在化疗方案中加入利妥昔单抗(免疫化疗),其国际预后指数(IPI)意义的变化。方法回顾性分析64例接受免疫化疗的侵袭性B细胞淋巴瘤患者的临床资料,分析免疫化疗后IPI预后意义的变化。结果在侵袭性B细胞淋巴瘤患者中,免疫化疗可以获得65.6%的持续完全缓解率,IPI中的分期(P=0.001)、血清LDH(P=0.042)对患者的疗效仍旧有影响;但根据IPI评分进行分组的4组患者之间,其预后差异无统计学意义(P=0.073)。结论免疫化疗在侵袭性B细胞淋巴瘤中可以获得较好的疗效,疾病的分期、血清LDH水平具有一定的预后意义,根据IPI进行的患者预后分组需要作进一步修订。Objective To investigate the impact of rituximab on the international prognostic index （IPI） in aggressive B cell lymphoma. Methods The data of 64 patients with aggressive B cell lymphomas who received rituximab-based treatment were analyzed retrospectively in order to find out the impact of rituximab on the IPI. Results Rituximab-based treatment could achieve a continues remission rate of 65.6% in aggressive B cell lymphoma. The stage of the disease and serum LDH levels could predict the outcomes of the disease, however, there was no significant difference in patients＇ prognosis among the four group divided according to IPI. Conclusion Rituximab-based treatment can get good outcome in patients with aggressive B cell lymphoma. The stage of the disease and serum LDH levels can predict the outcomes of the disease, while it need to be revised that the patients＇ prognosis is divided into different groups according to IPI.

关 键 词：侵袭性淋巴瘤 利妥昔单抗 国际预后指数 

分 类 号：R733[医药卫生—肿瘤]